Cardiac Holter Monitoring stands as a pivotal non-invasive diagnostic tool, capturing the intricate electrical symphony of the heart over an extended timeframe, typically ranging from 24 to 48 hours. Originating from the innovative work of Dr. Norman J. Holter, this diagnostic approach employs a portable device known as a Holter monitor, continuously documenting the heart's rhythm. The brilliance of this method lies in its ability to unveil irregularities that might elude detection during brief office visits. Specifically adept at uncovering sporadic cardiac issues like arrhythmias and palpitations, Cardiac Holter Monitoring provides a holistic perspective on the heart's electrical activity during various daily activities. This comprehensive data is invaluable for healthcare professionals, facilitating accurate diagnoses and the tailoring of precise treatment plans to optimize overall cardiac health.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States